Contineum Therapeutics stock falls after trial data delay

Published 25/06/2025, 13:40
© Reuters.

Investing.com -- Contineum Therapeutics Inc (NASDAQ:CTNM) stock fell 8.4% after the clinical-stage biopharmaceutical company announced a delay in reporting topline data from its Phase 1b trial of PIPE-791.

The company has completed enrollment of healthy volunteers and progressive multiple sclerosis (PrMS) patients in the trial but now expects to report topline data in the third quarter of 2025, representing what it described as a "modest delay." The postponement came after Contineum enrolled two additional PrMS patients in early June to assess PET imaging of the brain, in accordance with the trial protocol.

"While adding these additional patients to the trial has led to a modest delay in reporting our topline data, we believe the enhanced clinical understanding of PIPE-791 in patients is important to the program," said Timothy Watkins, Chief Medical (TASE:BLWV) Officer and Head of Development at Contineum Therapeutics.

The Phase 1b trial is evaluating PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The study aims to assess the correlation between pharmacokinetics and LPA1 receptor occupancy using positron emission tomography (PET) imaging in healthy volunteers and patients with progressive multiple sclerosis and idiopathic pulmonary fibrosis (IPF).

To date, 12 healthy volunteers and four PrMS patients have participated in the trial, with screening and enrollment of IPF patients still ongoing. The company is developing PIPE-791 for neuroscience, inflammation, and immunology indications.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.